Meihua (NASDAQ: MHUA) investors lock October and December placement shares for 12 months

Rhea-AI Filing Summary

Meihua International Medical Technologies Co., Ltd. reports that investors in its recent private placements have agreed to lock-up restrictions on their shares. The company previously completed an October offering of 40,000,000 ordinary shares (or 400,000 Class A ordinary shares on a post reverse-split and post re-designation basis) for gross proceeds of $15.2 million, and a December offering of up to 120,000 Class A ordinary shares for gross proceeds of $1.32 million. On January 22, 2026, all purchasers from both offerings entered into a lock-up agreement, committing for 12 months after each closing not to sell, pledge, or otherwise dispose of their Meihua securities or seek registration of those securities without the company’s prior written consent.

Insights

Capital markets and corporate finance analyst

Recent private placement investors agree to a 12‑month lock-up on their Meihua shares.

Meihua International Medical Technologies completed an October private placement for gross proceeds of $15.2 million and a December placement for gross proceeds of $1.32 million. The investors from both deals have now signed a lock-up that restricts them from selling or registering their securities for 12 months after the respective closings unless the company consents in writing.

The exhibit shows a separate lock-up form where signatories agree not to dispose of class A ordinary shares or related derivatives during the restriction period, with limited exceptions such as certain non-value transfers or option and warrant exercises, provided resulting shares remain subject to the lock-up. The company may use stop-transfer instructions to enforce these restrictions.

For investors, this arrangement means that shares issued in the October and December offerings are contractually restricted from being resold for a defined period, which can limit immediate secondary-market supply. The actual effect depends on how many purchasers hold sizable positions and whether any permitted transfers occur under the detailed conditions set out in the lock-up form.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission file number 001-41291

Meihua International Medical Technologies Co., Ltd.

(Translation of registrant’s name into English)

88 Tongda Road, Touqiao Town

Guangling District, Yangzhou, 225000

People’s Republic of China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒         Form 40-F  ☐

Investors’ Entry into the Lock-up Agreement

As previously disclosed, Meihua International Medical Technologies Co., Ltd. (the “Company”) entered into a securities purchase agreement with several “non-U.S. Persons” (the “October Purchasers”) as defined in Regulation S of the Securities Act of 1933, as amended (“the Securities Act”) on October 8, 2025 for a private placement of 40,000,000 ordinary shares of the Company, par value of $0.0005 per share, or 400,000 Class A ordinary Shares, par value $0.05 per share on a post reverse-split and post re-designation basis (the “Class A Ordinary Shares”), for gross proceeds of $15.2 million (the “October Offering”). The October Offering fully closed on January 20, 2026.

As previously disclosed, on December 5, 2025, the Company entered into a securities purchase agreement with certain “non-U.S. Persons” (the “December Purchasers”) as defined in Regulation S of the Securities Act, offering up to an aggregate of 120,000 Class A Ordinary Shares of the Company, for gross proceeds of $1,320,000 (the “December Offering”). The December Offering closed on December 15, 2025.

On January 22, 2026, each of the October Purchasers and the December Purchasers (collectively, the “Purchasers”) entered into a lock-up agreement (the “Lock-Up Agreement”) with the Company, pursuant to which the Purchasers agreed that, from the date of the Lock-Up Agreement until twelve (12) months following the closing of the October Offering and the December Offering, the Purchasers will not, without the prior written consent of the Company, offer, sell, contract to sell, hypothecate, pledge, or otherwise dispose of any securities of the Company beneficially owned, held, or thereafter acquired by the Purchaser (the “Securities”), or make any demand for, exercise any right to require, or cause to be filed any registration statement (or any amendment thereto) with respect to the registration of the Securities.

A form of the Lock-Up Agreement is furnished hereto as Exhibit 99.1 and such document is incorporated herein by reference. The foregoing is only a brief description of the material terms of the Lock-Up Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to such exhibit.

Exhibits

Exhibit No.		Description
99.1		Form of the Lock-Up Agreement

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Meihua International Medical Technologies Co., Ltd.
By:	/s/ Leyi Lee
Name:	Leyi Lee
Title:	Chief Executive Officer
Date: January 22, 2026

2

Exhibit 99.1

FORM OF LOCK-UP AGREEMENT

January [   ], 2026

Meihua International Medical Technologies Co., Ltd.

Re: Securities Purchase Agreement, dated as of [   ], 2025 (the “Agreement”), between Meihua International Medical Technologies Co., Ltd., a Cayman Islands company (the “Company”) and the purchasers signatory thereto (each a “Purchaser”, and collectively, the “Purchasers”)

Ladies and Gentlemen:

The undersigned irrevocably agrees with the Company that, from the date hereof until twelve (12) months following the closing of the offering (the “Offering”) of securities by the Company as described in the Agreement (such period, the “Restriction Period”), the undersigned will not, without the prior written consent of the Purchasers, offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the undersigned or any Affiliate of the undersigned or any person in privity with the undersigned or any Affiliate of the undersigned), directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), with respect to, any class A ordinary shares of the Company, par value of $0.05 per share (the “Ordinary Shares”) or securities convertible, exchangeable or exercisable into or for Ordinary Shares of the Company beneficially owned, held or hereafter acquired by the undersigned (the “Securities”) set forth on the signature page hereto, or make any demand for or exercise any right or cause to be filed a registration, including any amendments thereto, with respect to the registration of any shares of Ordinary Shares or Ordinary Shares equivalents or publicly disclose the intention to do any of the foregoing. Beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act. In order to enforce this covenant, the Company shall impose irrevocable stop-transfer instructions preventing the transfer agent of the Company from effecting any actions in violation of this Letter Agreement (as defined below).

Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer the Securities provided that (1) the Company receives a signed lock-up letter agreement (in the form of this letter agreement (the “Letter Agreement”)) for the balance of the Restriction Period from each donee, trustee, distributee, or transferee, as the case may be, prior to such transfer, (2) any such transfer shall not involve a disposition for value, (3) such transfer is not required to be reported with the Securities and Exchange Commission in accordance with the Exchange Act and no report of such transfer shall be made voluntarily, and (4) neither the undersigned nor any donee, trustee, distributee or transferee, as the case may be, otherwise voluntarily effects any public filing or report regarding such transfers, with respect to transfer:

i) as a bona fide gift or gifts;

ii) to any immediate family member or to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this Letter Agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin);

iii) to any corporation, partnership, limited liability company, or other business entity all of the equity holders of which consist of the undersigned and/or the immediate family of the undersigned;

iv) if the undersigned is a corporation, partnership, limited liability company, trust or other business entity (a) to another corporation, partnership, limited liability company, trust or other business entity that is an Affiliate of the undersigned or (b) in the form of a distribution to limited partners, limited liability company members or stockholders of the undersigned;

v) if the undersigned is a trust, to the beneficiary of such trust; or

vi) by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the undersigned, or

In addition, notwithstanding the foregoing, this Letter Agreement shall not restrict the delivery of Ordinary Shares to the undersigned upon (i) exercise of any options granted under any employee benefit plan of the Company; provided that any Ordinary Shares or Securities acquired in connection with any such exercise will be subject to the restrictions set forth in this Letter Agreement, or (ii) the exercise of warrants; provided that such Ordinary Shares delivered to the undersigned in connection with such exercise are subject to the restrictions set forth in this Letter Agreement.

Furthermore, the undersigned may enter into any new plan established in compliance with Rule 10b5-1 of the Exchange Act; provided that (i) such plan may only be established if no public announcement or filing with the Securities and Exchange Commission, or other applicable regulatory authority, is made in connection with the establishment of such plan during the Restriction Period and (ii) no sale of Ordinary Shares are made pursuant to such plan during the Restriction Period.

The undersigned acknowledges that the execution, delivery and performance of this Letter Agreement is a material inducement to the Company to complete the transactions contemplated by the Agreement, and of the Purchasers to enter into the Offering, and that the each of the Purchasers shall be beneficiary of this Letter Agreement and the Company shall be entitled to specific performance of the undersigned’s obligations hereunder. The undersigned hereby represents that the undersigned has the power and authority to execute, deliver and perform this Letter Agreement, that the undersigned has received adequate consideration therefor and that the undersigned will indirectly benefit from the closing of the transactions contemplated by the Offering.

2

This Letter Agreement may not be amended or otherwise modified in any respect without the written consent of each of the Company, the Purchasers and the undersigned. This Letter Agreement shall be construed and enforced in accordance with the laws of the State of New York without regard to the principles of conflict of laws. The undersigned hereby irrevocably submits to the exclusive jurisdiction of the United States District Court sitting in the Southern District of New York and the courts of the State of New York located in Manhattan, for the purposes of any suit, action or proceeding arising out of or relating to this Letter Agreement, and hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that (i) it is not personally subject to the jurisdiction of such court, (ii) the suit, action or proceeding is brought in an inconvenient forum, or (iii) the venue of the suit, action or proceeding is improper. The undersigned hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by receiving a copy thereof sent to the Company at the address in effect for notices to it under the Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. The undersigned hereby waives any right to a trial by jury. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. The undersigned agrees and understands that this Letter Agreement does not intend to create any relationship between the undersigned and any Purchaser and that no Purchaser is entitled to cast any votes on the matters herein contemplated and that no issuance or sale of the Securities is created or intended by virtue of this Letter Agreement.

This Letter Agreement shall be binding on successors and assigns of the undersigned with respect to the Securities and any such successor or assign shall enter into a similar agreement for the benefit of the Company. This Letter Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

Defined terms not otherwise defined in this Letter Agreement shall have the meanings set forth in the Agreement.

*** SIGNATURE PAGE FOLLOWS***

3

This Letter Agreement may be executed in two or more counterparts, all of which when taken together may be considered one and the same agreement.

__________________________

Signature

__________________________

Print Name

__________________________

Position in Company, if any

Address for Notice:

_______________________________

_______________________________

By signing below, the Company agrees to enforce the restrictions on transfer set forth in this Letter Agreement.

Meihua International Medical Technologies Co., Ltd.

By:

Name: 

Title:

[Signature Page to Lock-Up Agreement]

FAQ

What did Meihua International Medical Technologies (MHUA) disclose in this 6-K?

Meihua International Medical Technologies disclosed that investors in its recent private placements have entered into a 12-month lock-up agreement with the company, limiting their ability to sell or register the shares they purchased in those offerings without the company’s prior written consent.

How much capital did Meihua International Medical Technologies (MHUA) raise in the October and December offerings?

Meihua International Medical Technologies completed an October private placement of 40,000,000 ordinary shares (or 400,000 Class A ordinary shares on a post reverse-split and post re-designation basis) for gross proceeds of $15.2 million, and a December offering of up to 120,000 Class A ordinary shares for gross proceeds of $1,320,000.

What are the main terms of the new lock-up for MHUA’s October and December purchasers?

Each purchaser agreed that, for twelve months following the closing of the October and December offerings, they will not offer, sell, pledge, or otherwise dispose of Meihua securities they beneficially own or acquire, and will not demand or cause the filing of any registration statement for those securities, unless they first obtain the company’s written consent.

Who is subject to the lock-up related to Meihua International Medical Technologies (MHUA)?

The lock-up covers all investors who participated as October Purchasers and December Purchasers in Meihua’s Regulation S private placements. The exhibit also provides a lock-up form that can be signed by other holders, committing their class A ordinary shares and related securities to similar transfer and registration restrictions during the restriction period.

Does the lock-up agreement for MHUA allow any transfers or exercises during the restriction period?

The lock-up form allows certain limited transfers, such as non-value transfers where the recipient signs an identical lock-up, and permits delivery of shares upon option exercises under employee plans or warrant exercises, provided that any resulting shares remain subject to the same lock-up restrictions for the remainder of the period.

How are the lock-up restrictions for MHUA shares enforced?

The lock-up form states that the company may impose irrevocable stop-transfer instructions on its transfer agent to prevent actions that would violate the agreement. It also notes that the obligations are enforceable under New York law and that the United States District Court sitting in the Southern District of New York and New York state courts in Manhattan have exclusive jurisdiction over related disputes.